Roche to give up Tamiflu data; India fast-tracking price controls; Covis buys 5 Sanofi drugs;

@FiercePharma: India's top court rebuffs Merck, lets generic Januvia roll despite patent, at least for now. More | Follow @FiercePharma

@EricPFierce: FDA has no comment on judge's ruling to make Teva's Plan B available OTC to adolescents. Story | Follow @EricPFierce

> Roche ($RHHBY) is giving up its fight and will release its data on Tamiflu to researchers who have raised questions about its effectiveness. Story

> Switzerland-based specialty pharmaceutical company Covis Pharma has acquired the U.S. rights to 5 Sanofi ($SNY) drugs for an undisclosed amount. Release

> India may give drugmakers only 45 days to comply with new pricing for about 350 drugs it is putting under price controls, including batches already in the supply chain. News

> Biotest is recalling a lot of BIVIGAM Immune Globulin Intravenous (Human),10% Liquid after visible particles were found in some vials during an inspection. Statement

> Drug shortages continue to add to the concerns of cancer patients. Story

> Following Virgina's lead, the Florida legislature is on a path toward approving a law that would put restrictions on the use of biosimilars. Story

Medical Device News

@FierceMedDev: St. Jude faces fresh crop of Riata suits. Story | Follow @FierceMedDev

@MarkHFierce: David vs Goliath (J&J). David won. And then he lost on appeal. More | Follow @MarkHFierce

 @DamianFierce: Cancer Genetics is finally going public--at about 14% of its preliminary IPO pricing. News | Follow @DamianFierce

> J&J recalls Animas infusion pumps over hypoglycemia risk. Item

> J&J victory: Appeals court tosses $482M stent patent defeat. Story

> Swiss pick up baton for breath Dx research. More

Biotech News

@FierceBiotech: In case you missed it yesterday: Fierce's 10 top biotech billionaires. Special report | Follow @FierceBiotech

@JohnCFierce: Receptos--experienced team with CEO Faheem Hasnain (Facet)--files for IPO. S-1 | Follow @JohnCFierce.

@RyanMFierce: Looks like BMY and VRTX have struck another let's-see-what-happens deal in Hep C. Phase II only pact for now. Release | Follow @RyanMFierce

> Sarepta sustains high hopes for DMD drug eteplirsen with more PhII data. Article

> AstraZeneca reports hit-and-miss PhIII for arthritis pill. Report

> Astellas, Ambrx seal $300M cancer ADC deal. News

And Finally... Despite the public hue and cry on-going FDA inspections at compounding pharacies indicate many still didn't clean up their act. Story